» Articles » PMID: 29978150

Transcriptomic Profiling of Obesity-Related Nonalcoholic Steatohepatitis Reveals a Core Set of Fibrosis-Specific Genes

Overview
Journal J Endocr Soc
Specialty Endocrinology
Date 2018 Jul 7
PMID 29978150
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Nonalcoholic steatohepatitis (NASH) is strongly associated with obesity and type 2 diabetes. The molecular factors underlying the development of inflammation and severe fibrosis in NASH remain largely unknown. The purpose of this study was to identify gene expression patterns related to obesity-related NASH inflammation and fibrosis. We performed sequencing-based mRNA profiling analysis of liver samples from individuals with normal histology (n = 24), lobular inflammation (n = 53), or bridging fibrosis, incomplete cirrhosis, or cirrhosis (n = 65). Hepatic expression of a subset of mRNAs was validated using an orthogonal method, analyzed in a hepatic stellate cell line, and used to identify transcriptional patterns shared by other forms of cirrhosis. We observed evidence for differential levels of 3820 and 2980 transcripts in lobular inflammation and advanced fibrosis, respectively, compared with normal histology (false discovery rate ≤0.05), including 176 genes specific to fibrosis. Functional enrichment analysis of these genes revealed participation in pathways involving cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, focal adhesion, and extracellular matrix-receptor interaction. We identified 34 differentially expressed transcripts in comparisons of lobular inflammation and fibrosis, a proportion of which were also upregulated during activation of hepatic stellate cells. A set of 16 genes from a previous independent study of NASH bridging fibrosis/cirrhosis were replicated, several of which have also been associated with advanced fibrosis/cirrhosis due to hepatitis viruses or alcohol in human patients. Dysregulated mRNA expression is associated with inflammation and fibrosis in NASH. Advanced NASH fibrosis is characterized by distinct set of molecular changes that are shared with other causes of cirrhosis.

Citing Articles

Induction of MASH-like pathogenesis in the Nwd1 mouse liver.

Yamada S, Ogawa H, Funato M, Kato M, Nakadate K, Mizukoshi T Commun Biol. 2025; 8(1):348.

PMID: 40069352 PMC: 11897295. DOI: 10.1038/s42003-025-07717-5.


Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies.

Bourganou M, Chondrogianni M, Kyrou I, Flessa C, Chatzigeorgiou A, Oikonomou E Int J Mol Sci. 2025; 26(4).

PMID: 40004054 PMC: 11855544. DOI: 10.3390/ijms26041589.


Multidimensional landscape of non-alcoholic fatty liver disease-related disease spectrum uncovered by big omics data: Profiling evidence and new perspectives.

Zhu Z, Chen Y, Qin X, Liu S, Wang J, Ren H Smart Med. 2024; 2(2):e20220029.

PMID: 39188279 PMC: 11236021. DOI: 10.1002/SMMD.20220029.


MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives.

Karin M, Kim J Mol Oncol. 2024; 19(2):275-294.

PMID: 38874196 PMC: 11793012. DOI: 10.1002/1878-0261.13685.


Identification and validation of microbial biomarkers from cross-cohort datasets using xMarkerFinder.

Gao W, Lin W, Li Q, Chen W, Yin W, Zhu X Nat Protoc. 2024; 19(9):2803-2830.

PMID: 38745111 DOI: 10.1038/s41596-024-00999-9.


References
1.
Huang H, Wu T, Mao J, Fang Y, Zhang J, Wu L . CHI3L1 Is a Liver-Enriched, Noninvasive Biomarker That Can Be Used to Stage and Diagnose Substantial Hepatic Fibrosis. OMICS. 2015; 19(6):339-45. PMC: 4486713. DOI: 10.1089/omi.2015.0037. View

2.
Anders S, Pyl P, Huber W . HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2014; 31(2):166-9. PMC: 4287950. DOI: 10.1093/bioinformatics/btu638. View

3.
Patouraux S, Bonnafous S, Voican C, Anty R, Saint-Paul M, Rosenthal-Allieri M . The osteopontin level in liver, adipose tissue and serum is correlated with fibrosis in patients with alcoholic liver disease. PLoS One. 2012; 7(4):e35612. PMC: 3329460. DOI: 10.1371/journal.pone.0035612. View

4.
Asselah T, Bieche I, Laurendeau I, Paradis V, Vidaud D, Degott C . Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology. 2005; 129(6):2064-75. DOI: 10.1053/j.gastro.2005.09.010. View

5.
Staten N, Welsh E, Sidik K, McDonald S, Dufield D, Maqsodi B . Multiplex transcriptional analysis of paraffin-embedded liver needle biopsy from patients with liver fibrosis. Fibrogenesis Tissue Repair. 2012; 5(1):21. PMC: 3564743. DOI: 10.1186/1755-1536-5-21. View